CALGARY, Alberta--(BUSINESS WIRE)--Aspen Racing Stables, Inc. (OTCBB: ASRS) today announced that is has completed the acquisition of Kun Run Biotechnology Ltd. (“Kun Run”) in exchange for 24,250,000 newly issued shares. Kun Run owns 99.12% equity interest in Hainan Zhonghe Pharmaceutical Co., Ltd. (“Zhonghe”) which manufactures pharmaceutical products in Hainan, People’s Republic of China. Zhonghe’s principal products are polypeptide derivatives, sold primarily in China and through Chinese domestic pharmaceutical distributors licensed by the Chinese government.
